Veriskin

Veriskin is a medical device company dedicated to facilitating and improving the accuracy of skin cancer screening. Skin cancers are very difficult to diagnose and distinguish from non-cancerous skin abnormalities. This problem is exacerbated when a patient first presents to a primary care. Uncertainty in this initial assessment leads to (I) failure to detect cancer at an early, more treatable stage and loss of lives (27,000+ in the US), (II) hundreds of malpractice claims due to false negative diagnoses and, (III) many unnecessary referrals and biopsies that cost the US healthcare over $3B each year, monies that are unnecessarily wasted. Veriskin’s TruScore device is a proprietary, non-invasive, low-cost, hand-held unit that aids both dermatologists and non-expert clinicians to rapidly and objectively determine whether a suspect skin lesion is malignant, thereby reducing the number of false negatives and eliminating unneeded escalation of care and unnecessary biopsies. TruScore technology works by detecting both, structural and functional vascular abnormalities associated with the cancer-induced pathological angiogenesis which is a well-established early marker of cancer. Inherently higher information content from such measurements coupled with AI-assisted diagnostic algorithm provides for rapid, quantitative answers with >99% sensitivity and >94% specificity in differentiating any type of skin cancer from a variety of benign conditions. The clinical adoption of the device will benefit all three classes of stakeholders. Patients will benefit from non-invasive, painless procedure, less complications, immediate peace of mind and saved lives; Providers will gain diagnostic decision support, reduced liability due to false negatives, additional revenue and improved patient outcomes; Payors will save due to reductions in unnecessary specialist referrals and biopsies, and less expensive treatments due to early detection.